Esophageal Adenocarcinoma clinical trials

Explore recruiting esophageal adenocarcinoma clinical trials.

Recruiting esophageal adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Esophageal Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients with Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 overexpressing adenocarcinoma of the esophagus or gastroesophageal junction. The TRAP-2 study

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: a randomized phase II proof-of-concept study (BASALT)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II RAINSPOT: a multicentric open label trial of Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gastro-esophageal adenocarcinoma

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)

Romania, Ireland, Germany, Greece, Netherlands, Estonia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)

Belgium, Germany, Italy, Spain, Poland, Denmark +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Esophageal Adenocarcinoma trials by city

Esophageal Adenocarcinoma in Toronto Esophageal Adenocarcinoma in Vancouver Esophageal Adenocarcinoma in Montreal Esophageal Adenocarcinoma in Calgary Esophageal Adenocarcinoma in Edmonton Esophageal Adenocarcinoma in Ottawa Esophageal Adenocarcinoma in Winnipeg Esophageal Adenocarcinoma in Quebec City Esophageal Adenocarcinoma in Hamilton Esophageal Adenocarcinoma in Kitchener Esophageal Adenocarcinoma in London Esophageal Adenocarcinoma in Halifax Esophageal Adenocarcinoma in New York Esophageal Adenocarcinoma in Los Angeles Esophageal Adenocarcinoma in Chicago Esophageal Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease